Details for New Drug Application (NDA): 212287

✉ Email this page to a colleague

NDA 212287 describes PIPERACILLIN AND TAZOBACTAM, which is a drug marketed by Astral, Eugia Pharma, Eugia Pharma Speclts, Fresenius Kabi, Fresenius Kabi Usa, Hospira Inc, Istituto Bio Ita Spa, Provepharm Sas, Sagent Pharms Inc, Sandoz, Shandong, Steriscience Speclts, and Wockhardt Bio Ag, and is included in twenty-two NDAs. It is available from fourteen suppliers. Additional details are available on the PIPERACILLIN AND TAZOBACTAM profile page.

The generic ingredient in PIPERACILLIN AND TAZOBACTAM is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.

Tradename:	PIPERACILLIN AND TAZOBACTAM
Applicant:	Astral
Ingredient:	piperacillin sodium; tazobactam sodium
Patents:	0

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL
Approval Date:	Jul 29, 2019	TE:		RLD:	No

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL
Approval Date:	Jul 29, 2019	TE:		RLD:	No

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL
Approval Date:	Jul 29, 2019	TE:		RLD:	No

Complete Access Available with Subscription